Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid leukemia (AML). AMG 232 was administered orally once daily for 7 days every 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Erba, Harry P., Becker, Pamela S., Shami, Paul J., Grunwald, Michael R., Flesher, Donna L., Zhu, Min, Rasmussen, Erik, Henary, Haby A., Anderson, Abraham A., Wang, Eunice S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6616264/
https://ncbi.nlm.nih.gov/pubmed/31253596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019030916
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados